MELANOMA RECURRENT
Clinical trials for MELANOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new MELANOMA RECURRENT trials appear
Sign up with your email to follow new studies for MELANOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy hopes to boost immune attack on Hard-to-Treat melanoma
Disease control OngoingThis study tests a new drug called BI-1607 combined with two existing immunotherapies (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or cannot be removed. The goal is to see if adding BI-1607 helps the immune system better destroy cancer cells. A…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated May 26, 2026 05:52 UTC
-
New drug ST101 tested in patients with advanced cancers
Disease control OngoingThis study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
Could one year of immunotherapy be enough for advanced melanoma?
Disease control OngoingThis study looks at whether giving the immunotherapy drug pembrolizumab for one year works just as well as the usual two-year course for people with advanced melanoma that has spread. The trial involves 29 adults in Brazil whose melanoma cannot be removed by surgery or cured. The…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 26, 2026 05:43 UTC